

# Dosing and Administration<sup>1</sup>

## Recommended dose

The dose of Vascepa<sup>®</sup> is 4 grams/day taken as:

**Two 1 gram capsules**, twice daily with food



AM



PM

## Administration

Patients should be advised to swallow Vascepa<sup>®</sup> capsules whole. The patient should not break open, crush, dissolve, or chew Vascepa<sup>®</sup>.



## Missed dose

If the patient misses:

**One dose of Vascepa<sup>®</sup>**

They should take the dose as soon as they remember

**One day of Vascepa<sup>®</sup>**

They should not double the dose when they take their next dose


Vascepa<sup>®</sup> (icosapent ethyl) is indicated to reduce the risk of cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization or hospitalization for unstable angina) in statin-treated patients with elevated triglycerides, who are at high risk of cardiovascular events due to:

- ▶ established cardiovascular disease, or
- ▶ diabetes, and at least one other cardiovascular risk factor<sup>1</sup>



Co-pay card available to help get your patients started on Vascepa®  
—for more information, call  
1-833-999-6333.

Please consult the Vascepa® Product Monograph at <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp> for important information relating to contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use which have not been discussed in this piece.

The Product Monograph is also available by calling HLS Therapeutics Inc. at 1-833-266-3423.



The image shows a white oval pill with 'VASCEPA' embossed on it. To the left is the product name 'Pr Vascepa® (icosapent ethyl)'. Below the pill is a patient assistance card with a blue and purple header and an orange 'PATIENT ASSISTANCE' banner. The card contains a QR code, carrier and group numbers, a client ID, and the sti logo.

PATIENT ASSISTANCE			
	Carrier 32	Group 999	Client ID BRANDABCDE123MB 

To learn more, visit [www.vascepa.ca](http://www.vascepa.ca)

Reference:

1. HLS Therapeutics Inc. Vascepa® Product Monograph. 2019.

Vascepa® is a registered trademark of the Amarin group of companies.

© Copyright 2020 HLS Therapeutics Inc.  
HLS Therapeutics Inc.  
Etobicoke, Ontario  
M9W 6L2  
VAS 20200242 E COM



Pr **Vascepa**<sup>NEW</sup>  
(icosapent ethyl)